Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alkermes plc
  6. News
  7. Summary
    ALKS   IE00B56GVS15

ALKERMES PLC

(ALKS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Alkermes : to Take Part in the Goldman Sachs Annual Global Healthcare Conference

06/03/2021 | 06:39pm EDT

DUBLIN, June 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 10:30 a.m. ET (3:30 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com

Contact:
Alex Braun
Investor Relations
+1 781 296 8493

Alkermes plc Logo (PRNewsfoto/Alkermes plc)

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-to-take-part-in-the-goldman-sachs-annual-global-healthcare-conference-301305712.html

SOURCE Alkermes plc


ę PRNewswire 2021
All news about ALKERMES PLC
08/04INSIDER TRENDS : Alkermes Insider 90-Day Buying Trend Prolonged with Purchase
MT
08/02ALKERMES : Secures FDA Fast Track Designation for Melanoma Treatment
MT
08/02ALKERMES : Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Trea..
PR
08/02Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Tre..
CI
07/29ALKERMES : Reports Second Quarter 2021 Financial Results
AQ
07/29ALKERMES : Mizuho Securities Adjusts Alkermes' Price Target to $33 From $29, Mai..
MT
07/29ALKERMES : SVB Leerink Adjusts Alkermes' Price Target to $25 From $23, Keeps Mar..
MT
07/28ALKERMES : Reports Earnings, Revenue Increase for Q2, Raises Full-Year Guidance
MT
07/28ALKERMES : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
07/28ALKERMES : Q2 2021 Earnings slides Final 7 27 21 607pm.pdf
PU
More news